Good
Mostly Aligned
Patient Risk:
Low
Summary
Most extracted claims are supported by the supplied prescribing information (notably clinical study context, efficacy measures such as ORR and DOR, and hepatotoxicity monitoring). However, several claims are either unsupported/absent (time-to-response) or overgeneralized beyond what the provided label text directly supports (e.g., 'advanced/inoperable' phrasing and 'usually' for safety quantification across trial sections).
Category Scores
Accurate Statements
Turalio (pexidartinib) has been studied in clinical trials for tenosynovial giant cell tumor (TGCT).
14.1 Tenosynovial Giant Cell Tumor
In TGCT studies, pexidartinib trials evaluate how much the tumor shrinks.
14.1 (ORR assessed by RECIST v1.1; TVS defined in ENLIVEN)
In TGCT studies, pexidartinib trials evaluate how durable that response is over time.
14.1 (Duration of Response (DOR) and median duration of response results)
In TGCT studies, endpoints commonly include response rate based on imaging criteria.
14.1 (ORR assessed by blinded independent central review using RECIST v1.1)
In TGCT studies, endpoints commonly include duration of response.
14.1 (DOR presented; median duration of response discussed)
In TGCT studies, trials include safety/tolerability outcomes.
6.1 Clinical Trials Experience (serious adverse reactions, permanent discontinuation, dose reductions/interruption)
Pexidartinib carries important liver-related safety monitoring requirements.
5 WARNINGS AND PRECAUTIONS (Boxed Warning: hepatotoxicity; monitor liver tests prior to initiation and at specified intervals)
Clinical development of pexidartinib includes safety data collection for liver enzymes and other adverse events.
5 WARNINGS AND PRECAUTIONS (monitor liver tests); 6.1 Clinical Trials Experience (hepatic lab abnormalities and adverse reactions)
Safety findings for pexidartinib underpin boxed/warning and monitoring recommendations in prescribing information.
5 WARNINGS AND PRECAUTIONS and 6.1 Clinical Trials Experience (boxed warning and quantified hepatotoxicity/liver test abnormalities)
Unsupported Statements
In TGCT studies, endpoints commonly include time to response.
No 'time to response' endpoint is described in the provided label text (14.1).
Contradictions
Important Omissions
The AI claims do not specify the actual label-defined efficacy endpoints and assessment timing (e.g., ORR at Week 25; DOR results) when discussing 'shrinks'/'durability', which could be material for accurate interpretation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
All safety-related claims are descriptive of boxed warning/monitoring for hepatotoxicity and clinical trial safety characterization; no direct dosing or patient-specific recommendations are made.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
One claim is unsupported ('time to response'); two claims are partly supported due to overgeneralized language not explicitly present in the provided label text ('advanced/inoperable' wording; 'usually' across trial safety sections).
Suggested Improvement
Remove or rephrase unsupported/overgeneralized statements. For example, avoid 'time to response' unless the label explicitly lists it, and avoid asserting commonality ('key enrollment feature') using unlabeled terms like 'advanced/inoperable' unless supported verbatim or explicitly described in the provided text.